Azienda Ulss 2 Marca Trevigiana
8
2
2
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Dual REmission in Moderate-to-SEvere asthMa and Nasal Polyps
Role: lead
Multiparametric SCores for Prediction of Myocardial fIbrosis in Patients With MITral vAlve pRolapse
Role: collaborator
Monitoring COVID-19 Vaccination Response in Fragile Populations
Role: collaborator
POLE-END REAL LIFE: Endometrial Cancer Early Stages I-II and Advanced Stages III and IV Evaluation of POLE as a Prognostic Factor. Participants Are Women >= 18 Years Old, With the Pole Mutation
Role: lead
Conservative Management of CIN2 Lesions and Biomarkers Evaluation
Role: collaborator
Genetic Bases of COVID-19 Clinical Variability
Role: collaborator
IMMUNOlogical Microenvironment in REctal Adenocarcinoma Treatment.
Role: collaborator
IMMUNOlogical Microenvironment in REctal Adenocarcinoma Treatment
Role: collaborator
All 8 trials loaded